Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity
Aim. To study efficacy of treatment with liraglutide in women with type 2 diabetes (T2D) and obesity. Materials and methods. A group of 12 women aged 52-58 yr with T2D duration of 3-5 years, BMI 32-35 kg/m2, abnormally high C-peptide level,and НbА1с 7.5-8.5% were treated with 1500-2000 mg metformi...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN RU |
| Publicado: |
Endocrinology Research Centre
2011
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/aae89bec6f9d4226b7ae68f7f1b57120 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:aae89bec6f9d4226b7ae68f7f1b57120 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:aae89bec6f9d4226b7ae68f7f1b571202021-11-14T09:00:16ZExperience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity2072-03512072-037810.14341/2072-0351-5643https://doaj.org/article/aae89bec6f9d4226b7ae68f7f1b571202011-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/5643https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To study efficacy of treatment with liraglutide in women with type 2 diabetes (T2D) and obesity. Materials and methods. A group of 12 women aged 52-58 yr with T2D duration of 3-5 years, BMI 32-35 kg/m2, abnormally high C-peptide level,and НbА1с 7.5-8.5% were treated with 1500-2000 mg metformin/day and sulfonylureas at 50% of the maximum dose. Liraglutide was given insteadof sulfonylureas by a standard method (0.6 U/day for 1 week subcutaneously and 1.2 U/day thereafter). The total duration of therapy was 3 months.We analysed blood glucose level before and 2 hr after meals, НbА1с, lipidogram, C-peptide, HOMA index, BMI, waist circumference, percent of totalfat in the body, frequency of hypoglycemia, and side effects (nausea). Results. All patients achieved target values of НbА1с and a significant decrease in blood glucose before and after meals, body weight, total fat content,BMI, HOMA, systolic blood pressure; HDL cholesterol increased while LDL decreased. No case of hypoglycemia was documented. All the patientshad mild nausea of short duration (2-3 days). Conclusion. The use of liraglutide (Victoza) in women with T2D and obesity improve carbohydrate metabolism and insulin resistance without seriousside effects.Vladimir Ivanovich KudinovNatalya Vladimirovna ZolotarevaMaria Sergeeva NichitenkoEndocrinology Research Centrearticlediabetesliraglutidecompensaionobesitylipidogramsystolic blood pressureNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 14, Iss 2, Pp 91-93 (2011) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN RU |
| topic |
diabetes liraglutide compensaion obesity lipidogram systolic blood pressure Nutritional diseases. Deficiency diseases RC620-627 |
| spellingShingle |
diabetes liraglutide compensaion obesity lipidogram systolic blood pressure Nutritional diseases. Deficiency diseases RC620-627 Vladimir Ivanovich Kudinov Natalya Vladimirovna Zolotareva Maria Sergeeva Nichitenko Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity |
| description |
Aim. To study efficacy of treatment with liraglutide in women with type 2 diabetes (T2D) and obesity. Materials and methods. A group of 12 women aged 52-58 yr with T2D duration of 3-5 years, BMI 32-35 kg/m2, abnormally high C-peptide level,and НbА1с 7.5-8.5% were treated with 1500-2000 mg metformin/day and sulfonylureas at 50% of the maximum dose. Liraglutide was given insteadof sulfonylureas by a standard method (0.6 U/day for 1 week subcutaneously and 1.2 U/day thereafter). The total duration of therapy was 3 months.We analysed blood glucose level before and 2 hr after meals, НbА1с, lipidogram, C-peptide, HOMA index, BMI, waist circumference, percent of totalfat in the body, frequency of hypoglycemia, and side effects (nausea). Results. All patients achieved target values of НbА1с and a significant decrease in blood glucose before and after meals, body weight, total fat content,BMI, HOMA, systolic blood pressure; HDL cholesterol increased while LDL decreased. No case of hypoglycemia was documented. All the patientshad mild nausea of short duration (2-3 days). Conclusion. The use of liraglutide (Victoza) in women with T2D and obesity improve carbohydrate metabolism and insulin resistance without seriousside effects. |
| format |
article |
| author |
Vladimir Ivanovich Kudinov Natalya Vladimirovna Zolotareva Maria Sergeeva Nichitenko |
| author_facet |
Vladimir Ivanovich Kudinov Natalya Vladimirovna Zolotareva Maria Sergeeva Nichitenko |
| author_sort |
Vladimir Ivanovich Kudinov |
| title |
Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity |
| title_short |
Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity |
| title_full |
Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity |
| title_fullStr |
Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity |
| title_full_unstemmed |
Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity |
| title_sort |
experience of the use of liraglutide (victoza) in women with type 2 diabetes mellitus and obesity |
| publisher |
Endocrinology Research Centre |
| publishDate |
2011 |
| url |
https://doaj.org/article/aae89bec6f9d4226b7ae68f7f1b57120 |
| work_keys_str_mv |
AT vladimirivanovichkudinov experienceoftheuseofliraglutidevictozainwomenwithtype2diabetesmellitusandobesity AT natalyavladimirovnazolotareva experienceoftheuseofliraglutidevictozainwomenwithtype2diabetesmellitusandobesity AT mariasergeevanichitenko experienceoftheuseofliraglutidevictozainwomenwithtype2diabetesmellitusandobesity |
| _version_ |
1718429603906715648 |